Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
LUNG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.46 - $10.01
Previous CloseN/A
Volume95.69K
Average Volume (3M)422.34K
Market Cap
$269.02M
Enterprise Value$223.49M
Total Cash (Recent Filing)$70.91M
Total Debt (Recent Filing)$56.47M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 06, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding39,796,420
10 Day Avg. Volume314,159
30 Day Avg. Volume422,343
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.69
Price to Cash Flow (P/CF)-11.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda-3.87
Forecast
1Y Price Target
$13.17Price Target Upside93.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Pulmonx News
PremiumCompany Announcements
Pulmonx Corporation’s Earnings Call Reveals Strong Growth and Challenges
PremiumCompany Announcements
Pulmonx Corporation Achieves Record Revenue Growth in 2024
---
Bulls Say, Bears Say
Bulls Say
Growth InitiativesBoth Mr. Williamson and Mr. Joshi are leveraging their past commercial leadership experience to drive initiatives that should help the company achieve its >20% long-term growth target.
ProfitabilityManagement remains confident in achieving cash flow profitability with cash on hand and expects moderated cash burn going forward, through maintaining discipline on operating expenses.
Revenue GuidanceManagement issued FY25 guidance that is ahead of company estimates, indicating confidence in continued growth driven by strategic initiatives.
Bears Say
Management TurnoverDespite management turnover and broader MedTech weakness, the current team has been executing effectively to numbers.
Operating ExpensesManagement expects leverage in SG&A this year, with operating expense growth primarily driven by higher R&D costs associated with the CONVERT II trial enrollment expenses.
---
Ownership Overview
11.55% Insiders
35.14% Mutual Funds
32.16% Other Institutional Investors
5.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $5.46 and its highest was $10.01 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $269.02M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is May 06, 2025 which is in 31 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Feb 19, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.447 by $0.117.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.4.
How many shares outstanding does Pulmonx have?
Pulmonx has 39,796,420 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.447. Following the earnings report the stock price went up 32.229%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
---
Pulmonx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.17 (93.11% Upside)
$13.17 (93.11% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $103.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.96%
12-Months-Change
Fundamentals
Return on Equity
-55.25%
Trailing 12-Months
Asset Growth
-6.28%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
---
LUNG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Pulmonx demonstrated strong revenue growth and international expansion, with significant advancements in clinical trials and product innovation. However, increased operating expenses and persistent net losses highlight ongoing financial challenges. The future outlook includes strategic initiatives to sustain growth, but foreign exchange fluctuations pose a potential risk.Read More>---
LUNG Stock 12 Month Forecast
Average Price Target
$13.17
▲(93.11% Upside)
Technical Analysis
Insulet
―
NovoCure
―
Irhythm Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Best Analysts Covering LUNG
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-25.95%
reiterated a buy rating last month
Copying Jason Bednar's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -25.95% per trade.
---